The acquisition brings MLM’s operations in the United States, Germany, and South Africa into Labcorp’s global laboratory network.
Labcorphas acquired MLM Medical Labs (MLM), a global central and specialty laboratory provider, to expand its clinical trial laboratory capabilities across key research markets.
The deal strengthens Labcorp’s biomarker and specialty testing services while extending its wholly owned laboratory network across four continents.
Financial details of the transaction have not been disclosed.
MLM also operates Africa’s first fully CAP-accredited central
MLM also operates Africa’s first fully CAP-accredited central laboratory, adding specialised infrastructure and regulatory capabilities to Labcorp’s network.
“Clinical trial sponsors today need scientific expertise, global reach, and operational flexibility to advance increasingly complex development programs,” said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. “MLM complements Labcorp’s existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies. Together, we are well positioned to provide the capabilities, regional expertise and high-touch support sponsors need to advance innovative therapies worldwide.”
With MLM Medical Labs now part of its operations, Labcorp expects to offer broader biomarker and specialty testing capabilities while supporting multinational trials through a more integrated laboratory infrastructure.
The combined network is also intended to provide consistent scientific, operational, and regulatory oversight across multiple research regions.
Stay tuned for more such updates on Digital Health News
